Login / Signup

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.

Francisco Cezar Aquino de MoraesEric PasqualottoMatheus Pedrotti ChavezRafael Oliva Morgado FerreiraTiago Biachi de CastriaRommel Mario Rodríguez Burbano
Published in: BMC cancer (2024)
In this comprehensive systematic review and meta-analysis of RCTs, the incorporation of Zolbetuximab alongside chemotherapy offers a promising prospect for reshaping the established treatment paradigms for patients diagnosed with advanced CLDN18.2-positive GC/GEJ cancer.
Keyphrases